Hepatitis is a global public health problem affecting millions of people worldwide, causing both short-term and long-term liver diseases. On the occasion of World Hepatitis Day (WHD), which occurs on July 28 every year, Tianlong Technology (“Tianlong”), a high-tech company specializing in medical innovation in China, is spearheading solutions for the early diagnosis, detection, and treatment of the disease.
Any kind of hepatitis that develops for a long time will cause serious damage to human health and can even present a threat to life. To raise people’s awareness of the problem of viral hepatitis, the World Health Organization (WHO), has proclaimed “We’re Not Waiting” as the campaign theme for WHD 2023.
In response to the action for WHD, Tianlong has developed Hepatitis B (HBV) and Hepatitis C (HCV) nucleic acid detection kits and genotyping detection kits that are highly sensitive, accurate, and easy to operate. These kits, when applied with Tianlong's self-developed instruments for automated nucleic acid extraction and fluorescence quantitative PCR detection, enable automatic nucleic acid detection in just two hours.
The ultra-sensitive HBV DNA and HCV RNA detection kit developed by Tianlong is particularly suitable for low viral load patients, providing accurate diagnosis and treatment of HBV and HCV. The reagent is designed with a UNG enzyme + dUTP anti-pollution system to prevent product contamination caused by false positive results.
In China, Tianlong’s innovative technology led to the formulation of the national pharmaceutical industry standard of the nucleic acid extraction kit (magnetic beads method). Guaranteed by standardized reagents and automatic instruments, the detection sensitivity, accuracy, and repeatability have been greatly improved, which provides much more accurate detection results for clinical diagnosis and treatment. Thanks to its reliable performance, Tianlong’s HBV&HCV detection solution has been widely used by hospitals, public health centers, and CDCs. In Thailand, Tianlong’s HBV&HCV detection solution has been successively applied in public hospitals, and soon will be seen in more countries and regions.
Tianlong is committed to rolling out innovative products to help achieve the global goal of eliminating hepatitis by 2030. With the continued development of treatment and diagnostic technology, the possibility of achieving this goal will be greatly enhanced.
